Recommendation of first chikungunya vaccine for persons as young as 12 years old expands access for US travelers to regions with outbreak or ...

The U.S. Centers for Disease Control's vaccine advisory committee voted to recommend the single-dose vaccine, Vimkunya, for the prevention chikungunya in 12 years and older traveling to a country ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The updated recommendations are pending final approval by the director of the CDC and the Department of Health and Human Services.

For meningococcal vaccines, ACIP recommended that GSK's pentavalent vaccine (Penmenvy), designed to protect against A, B, C, ...

Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age ...

A two-day meeting of the Advisory Committee on Immunization Practices (ACIP), which was originally scheduled for February but ...

Discover why BVNKF's vaccine innovations, growth catalysts, and compelling valuation after a 52% pullback make it a strong ...

The chikungunya ... heterologous alphavirus vaccines,” the authors wrote. This study received funding from the Defense Health Program, Emergent Travel Health, and Bavarian Nordic A/S.

Commercial for North America at Bavarian Nordic. “As the first virus-like particle single-dose, pre-filled syringe chikungunya vaccine, Vimkunya provides a crucial new tool to help protect at ...